Navigation Links
Peptimmune Presents Early Clinical Data at European Neurological Society and Federation of Clinical Immunology Societies Meetings
Date:6/9/2008

CAMBRIDGE, Mass., June 9 /PRNewswire/ -- Peptimmune, Inc., a privately held biotechnology company, presented early clinical results from its PI-2301 peptide copolymer program at both the 17th Annual ENS meeting in Nice, France and at FOCIS 2008 in Boston, MA. The Company presented data from its Phase Ia Single-Ascending-Dose, first-in-man study involving healthy, male adult volunteers following SC administration of the second-generation peptide copolymer PI-2301. This study demonstrated that all doses were safe and well tolerated, and demonstrated early immunological effects of PI-2301 consistent with its pharmacologic mechanism of action.

The Phase I single-ascending dose, double-blind placebo, controlled-randomized study involved fifty-six healthy volunteers who received the drug in eight escalating dose cohorts. All doses were safe and well tolerated (0.035 - 60mg), and there were no serious adverse events. Pharmacodynamic assays demonstrated evidence of immune exposure (tritium uptake, IL-13 in recall responses) consistent with the pharmacologic mechanism of action for PI-2301, and dose-related pharmacokinetics were observed (proprietary antibody-based assay). The Company plans to initiate its first repeat-dose study in multiple sclerosis patients in Q2/2008.

Peptimmune also presented data that details significant differences in the bioavailability, mechanism of action, and pharmacodynamic effects between PI-2301 and Copaxone(R) (Teva Pharmaceuticals). The Company demonstrated four-fold greater bioavailabilty of PI-2301 than Copaxone, and a significantly greater regulatory immune response than Copaxone. Both presentations are available on Peptimmune's Web site at http://www.peptimmune.com/research_development/publications.

"We are pleased to see that PI-2301 was well tolerated and that this trial has provided evidence of PI-2301's immunomodulatory
'/>"/>

SOURCE Peptimmune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Peptimmune Completes Phase I Study with a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
2. Peptimmune Initiates Phase I Study With a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
3. Genaera Corporation Presents Additional Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at American Diabetes Association
4. EntreMed Presents MKC-1 Phase 2 Data at American Society of Clinical Oncology Annual Meeting
5. ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
6. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
7. Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and Clinical Update on ProLindac(TM) Development at Prestigious International Symposium
8. Access Pharmaceuticals Presents New Data on the Companys Cobalamin(TM) Technology at an International Polymer Therapeutics Symposium
9. Abbott Presents Long-Term Data From Extension Study Showing Adult Crohns Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission
10. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
11. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... Calif. , May 28, 2015  Based ... market, Frost & Sullivan recognizes Lexmark Healthcare ... Sullivan Award for Company of the Year in ... take HCM to the next level of interoperability ... acquisitions and followed them up with large-scale product ...
(Date:5/28/2015)... , May 26, 2015 Research ... of the "2015 Strategies in the US ... Market" report to their offering. ... provides comprehensive analysis of the diagnostic testing markets ... ICUs). The report includes analysis of the market ...
(Date:5/28/2015)... -- Cypher Genomics, Inc., the leading genome ... announced a collaboration in which Cypher,s automated genomic interpretation ... genetic diseases among a unique population. Located in ... Children (CSC) serves many Amish and Mennonite patients, a ... disease. "We are very excited to ...
Breaking Medicine Technology:Frost & Sullivan Acknowledges Lexmark Healthcare's Energy, Creativity, and Diligence in Developing the Leading Next-Generation Healthcare Content Management Platform 2Frost & Sullivan Acknowledges Lexmark Healthcare's Energy, Creativity, and Diligence in Developing the Leading Next-Generation Healthcare Content Management Platform 3Frost & Sullivan Acknowledges Lexmark Healthcare's Energy, Creativity, and Diligence in Developing the Leading Next-Generation Healthcare Content Management Platform 4Frost & Sullivan Acknowledges Lexmark Healthcare's Energy, Creativity, and Diligence in Developing the Leading Next-Generation Healthcare Content Management Platform 5Strategies in the US Ancillary Hospital Locations (ERs, ORs, ICUs) Diagnostic Testing Market 2015-2020 2Cypher Genomics and Clinic for Special Children Collaborate on Rare Disease Study 2Cypher Genomics and Clinic for Special Children Collaborate on Rare Disease Study 3
... -- BERGISCH GLADBACH, Germany, September 22, 2010 ... ... ... Results are keyed by longUrl, so we need to grab the first one. for (var r in ...
... With a company rank on this year,s list ... list of companies who have surpassed expectations during ... (Logo: http://photos.prnewswire.com/prnh/20100817/INC5000LOGO ) (Logo: ... List honors the fastest growing private companies in ...
Cached Medicine Technology:Direct Isolation of Primary Astrocytes With Anti-GLAST MicroBeads 2Direct Isolation of Primary Astrocytes With Anti-GLAST MicroBeads 3Direct Isolation of Primary Astrocytes With Anti-GLAST MicroBeads 4Direct Isolation of Primary Astrocytes With Anti-GLAST MicroBeads 5Direct Isolation of Primary Astrocytes With Anti-GLAST MicroBeads 6
(Date:5/28/2015)... San Francisco,CA (PRWEB) May 28, 2015 ... to creating technology that advances sexual health and ... that the University of San Francisco (USF) will ... online college sexual assault recording and reporting system. ... more empowering, transparent, and confidential reporting experience for ...
(Date:5/28/2015)... May 28, 2015 lifeIMAGE ... round of financing led by Cambia Health Solutions ... dedicated to transforming health care by creating a person-focused ... most utilized network for exchanging medical imaging, will use ... base, increase the breadth of its network capabilities and ...
(Date:5/28/2015)... Optimity Advisors ( Optimity ) ... of care for healthcare organizations worldwide – today ... help operationalize contracting and engagement models. As part ... series of seven “ OrangePapers” that provide ... is a strategy, operations and information technology advisory ...
(Date:5/28/2015)... 28, 2015 WebWatcher, the ... their partnership with BeSure Consulting to help ... The partnership will combine BeSure Consulting’s ... parental monitoring software solution. , Led by ... Consulting's passion is concentrated on teaching law ...
(Date:5/28/2015)... Cancer survivors who participated in the LIVESTRONG ... fitness and quality of life, according to research conducted ... Jennifer Ligibel, MD, senior physician in the Susan F. ... The findings will be presented at this year’s ... in Chicago. , The study, designed to ...
Breaking Medicine News(10 mins):Health News:University of San Francisco Becomes First in the Nation to Adopt College Sexual Assault Reporting System 2Health News:University of San Francisco Becomes First in the Nation to Adopt College Sexual Assault Reporting System 3Health News:Cambia Health Solutions Leads New Round of Investment in lifeIMAGE 2Health News:Cambia Health Solutions Leads New Round of Investment in lifeIMAGE 3Health News:Cambia Health Solutions Leads New Round of Investment in lifeIMAGE 4Health News:Optimity Advisors Now Offers Outcomes Based Contracting Services to Support Engagement Model For New Healthcare Innovative Models of Care 2Health News:WebWatcher Partners with BeSure Consulting 2Health News:WebWatcher Partners with BeSure Consulting 3Health News:LIVESTRONG at the YMCA Program Shows Significant Gains for Cancer Survivor Participants 2Health News:LIVESTRONG at the YMCA Program Shows Significant Gains for Cancer Survivor Participants 3Health News:LIVESTRONG at the YMCA Program Shows Significant Gains for Cancer Survivor Participants 4
... Nov. 3 The Guardian Life Insurance Company ... benefit enrollment,services by adding more features to serve ... Census Bureau, Spanish speakers constitute 12,percent of the ... has introduced customized Spanish-language benefit enrollment,kits, with everything ...
... Genoveva (“Gigi”) Garcia, a 91-year-old movie buff who once was a ... final reel in her life has a surprising twist: Her granddaughter, ... sharing her riches-to-rags-to-riches story with others on CarePages.com, a community of ... , ...
... 3 Paul Offit, MD,announced today that all author ... False Prophets: Bad Science, Risky Medicine, and the Search,for ... Autism Research at,Children,s Hospital of Philadelphia., (Photo: ... with Dr. Offit, and to accept the,royalties of his ...
... scientists have discovered a mechanism by which intracellular pathogens ... weapons against them: nitric oxide. The researchers found that ... biochemical machinery used by immune cells called macrophages to ... tanks of the immune system, attacking and consuming bacteria ...
... in detecting airway stent complications according to a recent ... Harvard Medical School in Boston, MA. , MDCT ... patients, including all cases of intraluminal narrowing, migration, invasion ... of four cases of stent fracture," according to Vandana ...
... or surgical procedures for children with suspected musculoskeletal ... study performed at Vanderbilt Children,s Hospital in Nashville, ... on 130 children with suspected musculoskeletal infections; 34 ... after diagnostic or therapeutic intervention and 96 patients ...
Cached Medicine News:Health News:Guardian Enhances Enrollment Capabilities With More Spanish Language Services 2Health News: Jennifer & Gigi: A Story of Love and Compassion with a Hollywood Twist -- In honor of National Family Caregivers Month, CarePages.com celebrates "Grandma Gene" and gives a voice to the community of caregivers around the world 2Health News: Jennifer & Gigi: A Story of Love and Compassion with a Hollywood Twist -- In honor of National Family Caregivers Month, CarePages.com celebrates "Grandma Gene" and gives a voice to the community of caregivers around the world 3Health News:Author Royalties From Autism Book Donated to Autism Research 2Health News:Parasites that live inside cells use loophole to thwart immune system 2Health News:Parasites that live inside cells use loophole to thwart immune system 3
Xenon technology achieves a higher efficiency than halogen light sources. Consequently they provide more light....
This single lamp light source is perfect for surgeon's offices, cath labs, dermatology offices, and specialty uses....
Delivers one primary lamp and one backup lamp. The port accepts ACMI fiberoptic cables....
The 300W effective dual light source has quality xenon performance....
Medicine Products: